Levomilnacipran

Medical uses

Levomilnacipran is indicated for the treatment of major depressive disorder in adults.

Side effects

Side effects seen more often with levomilnacipran than with placebo in clinical trials included nausea, dizziness, sweating, constipation, insomnia, increased heart rate and blood pressure, urinary hesitancy, erectile dysfunction and delayed ejaculation in males, vomiting, tachycardia, and palpitations.

Pharmacology

Pharmacodynamics

Relative to other serotonin and norepinephrine reuptake inhibitors, levomilnacipran, as well as milnacipran, differ in that they are much more balanced reuptake inhibitors of serotonin and norepinephrine. To demonstrate, the serotonin:norepinephrine ratios of SNRIs are as follows: venlafaxine = 30:1, duloxetine = 10:1, desvenlafaxine = 14:1, milnacipran = 1.6:1, and levomilnacipran = 1:2. The clinical implications of more balanced elevations of serotonin and norepinephrine are unclear, but may include improved effectiveness, though also increased side effects.

Levomilnacipran is selective for the serotonin and norepinephrine transporters, lacking significant affinity for over 23 off-target sites. However, it does show some affinity for the dizocilpine (MK-801/) site of the NMDA receptor (Ki = 1.7 μM), and has been found to inhibit NR2A and NR2B subunit-containing NMDA receptors with respective IC50 values of 5.62 and 4.57 μM. As such, levomilnacipran is an NMDA receptor antagonist at high concentrations.

Pharmacokinetics

Levomilnacipran has a high oral bioavailability of 92% and a low plasma protein binding of 22%. It is metabolized in the liver by the cytochrome P450 enzyme CYP3A4, thereby making the medication susceptible to grapefruit-drug interactions. The drug has an elimination half-life of approximately 12 hours, allowing for once-daily administration. Levomilnacipran is excreted in urine.

History

Levomilnacipran was developed by Forest Laboratories and Pierre Fabre Group, and was approved by the US Food and Drug Administration in July 2013. The FDA approved levomilnacipran for treating major depressive disorder. The approval was based on the results of five clinical trials. The trials included one 10-week phase II and four 8-week phase III. Four of the five trials demonstrated a statistically significant superiority to placebo as measured by the Montgomery–Åsberg Depression Rating Scale. Superiority to placebo was also demonstrated by improvement in the Sheehan Disability Scale.

Research

Levomilnacipran has been found to act as an inhibitor of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), which is responsible for β-amyloid plaque formation, and hence may be a potentially useful drug in the treatment of Alzheimer's disease.

References

References

1. Anvisa. (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial". [[Diário Oficial da União]].
2. (7 July 2016). "Product monograph brand safety updates".
3. (4 May 2016). "Health Canada New Drug Authorizations: 2015 Highlights".
4. (19 April 2024). "Fetzima- levomilnacipran hydrochloride capsule, extended release; Fetzima- levomilnacipran hydrochloride kit".
5. (22 December 2008). "Pierre Fabre Medicament and Forest Laboratories to Collaborate on Development and Commercialization of F2695 for Depression". FierceBiotech.
6. (1998). "Which bioequivalence study for a racemic drug? Application to milnacipran". European Journal of Drug Metabolism and Pharmacokinetics.
7. (14 March 2014). "Drug Approval Package: Fetzima (levomilnacipran) Extended-Release Capsules NDA #204168".
8. (February 2014). "A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder". Journal of Clinical Psychopharmacology.
9. (March 2014). "Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison". Innovations in Clinical Neuroscience.
10. (August 2014). "Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder". Journal of Pharmacy Practice.
11. (September 2010). "Milnacipran: a unique antidepressant?". Neuropsychiatric Disease and Treatment.
12. (August 2013). "Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials". Journal of Psychopharmacology.
13. (September 2013). "Levomilnacipran extended release: first global approval". Drugs.
14. (10 May 2017). "The American Psychiatric Association Publishing Textbook of Psychopharmacology". American Psychiatric Pub.
15. (31 March 2017). "Prescriber's Guide: Stahl's Essential Psychopharmacology". Cambridge University Press.
16. (November 2013). "Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?". International Journal of Clinical Practice.
17. (2014). "Fetzima (levomilnacipran), a drug for major depressive disorder as a dual inhibitor for human serotonin transporters and beta-site amyloid precursor protein cleaving enzyme-1". CNS & Neurological Disorders Drug Targets.